Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue SarcomaYasuyoshi Sato, Shunji Takahashi, Naomi Hayashi et al.|Cancers|2021Cited by 12
Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment lineKenji Nakano, Shunji Takahashi, Keiko Hayakawa et al.|Molecular and Clinical Oncology|2020Cited by 9
Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue SarcomaYasuyoshi Sato, Shunji Takahashi, Kenji Nakano et al.|Anticancer Research|2021Cited by 8
Retrospective Analysis of Trabectedin Therapy for Soft Tissue SarcomaKuniki Kawaguchi, Shunji Takahashi, Kenji Nakano et al.|In Vivo|2019Cited by 7
Changes in Neutrophil-to-lymphocyte Ratio Predict Efficacy of Trabectedin for Soft-tissue SarcomaYasuyoshi Sato, Shunji Takahashi, Kenji Nakano et al.|Cancer Diagnosis & Prognosis|2021Cited by 5